First-Quarter 2022 Earnings
Strong Performance Driven By Pandemic Recovery
First-Quarter 2022 Business Drivers¹
Product Category
Renal Care
Medication Delivery
Pharmaceuticals
Clinical Nutrition
Advanced Surgery
Acute Therapies
BioPharma Solutions
Hillrom
Baxter
Sales
$894M
$706M
$521M
$227M
$228M
$188M
$156M
$755M
CC Growth² Quarterly Performance Drivers
+1%
+10%
(2%)
+1%
+8%
(7%)
+21%
N/A
Performance driven by growth in PD business reflecting a year-over-year increase in
global patient volumes; partially offset by lower In-Center HD dialyzer sales
internationally
Strong U.S. growth reflects continued recovery in the pace of hospital admissions
as well as increased demand for IV administration sets and solutions; sales also
benefited from lower customer rebates
Performance negatively impacted by increased competition for select molecules in
U.S. generic injectables portfolio, lower sales of inhaled anesthetics and pandemic
related supply constraints
Performance driven by new product launches within broad
multichamber product offering
Growth reflects elective procedure recovery in the U.S. and Europe; partially offset
by APAC region which experienced somewhat depressed levels of surgical volumes
Reflects a challenging comparison to first-quarter 2021 when demand for CRRT
was elevated given the rise in COVID-19 cases
Strong performance driven by multiple collaborations to help manufacture
COVID-19 vaccines on a contract basis
Hillrom contributed $755 million in sales to the quarter
¹Non-GAAP financial metrics referenced in this slide include constant currency sales growth.
A reconciliation to comparable U.S. GAAP measures can be found herein and is available at www.baxter.com. 2Represents growth at constant currency, adjusting for the impact of foreign exchange.
COView entire presentation